A Phase 2 interventional study of Hyperbaric Oxygen Therapy (HBOT) in Traumatic Brain Injury (TBI) Patients, Post Concussive Symptoms and PTSD, sponsored by Summit Hyperbarics and Wellness. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Summit Hyperbarics and Wellness · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Post-Concussion Syndrome with a site in United States — 15 open to participants now, 20 under way, 1 of them phase 3. Post-Concussion Syndrome · United States.
Among the 77 studies in Post-Concussion Syndrome with a site in United States, this one is the 35th largest by planned enrollment of the 61 interventional ones that give a count, is one of 7 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 14 of the 19 other live ones, and was the 75th registered.
140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.
Browse Post-Concussion Syndrome studies →15 of the 77 studies in Post-Concussion Syndrome with a site in United States are open now. Recruiting first, the newest first:
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Summit Hyperbarics and Wellness · Sites in United States
Ages 18+
Neuroscience Group · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 20–85 · Healthy volunteers
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Post-Concussion Syndrome studies recruiting now, 3 (13%) set no upper age limit and 20 (83%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 15 · Phase 3 2 · Phase 4 2
First in 2004; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34 is below the median of 52 across 113 interventional studies indexed under Post-Concussion Syndrome.
Median enrollment 40 across the 61 interventional studies, 90 across the 16 observational. Of the 51 that completed or were terminated, 13 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 77 have an industry lead sponsor. The 10 most frequent:
Summit Hyperbarics and Wellness is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Summit Hyperbarics and Wellness has 4 studies filed under Post-Concussion Syndrome — fewer than ten, so there is no comparison to draw.
8 of the studies in Post-Concussion Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04978571Children's Hospital of Orange CountyPercutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS) | 2026-12 |
| NCT07303933Penn State UniversityFemale Concussion Head Cooling | 2027-01-01 |
| NCT07044596University of Wisconsin, MadisonNon-invasive Stimulation of the Glymphatic System for Slowing Cognitive Decline | 2027-06 |
| NCT07732374Summit Hyperbarics and WellnessLong-Term Outcomes Following HBOT | 2027-06-18 |
| NCT04760899University of IowaCerebellar TDCS for SRPCS Treatment | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 77 studies in Post-Concussion Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to examine changes in blood biomarkers following hyperbaric oxygen therapy (HBOT) in military veterans with traumatic brain injury and persistent post-concussive symptoms. The main questions it aims to answer are:
Participants will:
Complete medical and behavioral health evaluations to determine eligibility. Provide blood samples before treatment and after the final session. Receive 40 HBOT sessions at 2.0 ATA, generally two sessions per day with at least four hours between sessions.
Approximately 34 veterans will participate. All participants will receive HBOT; there is no comparison group.
This prospective, single-group study will evaluate changes in blood biomarkers following hyperbaric oxygen therapy (HBOT) in approximately 34 military veterans with a history of traumatic brain injury (TBI) and persistent post-concussive symptoms (PCS). The primary objective is to assess changes from baseline to completion of treatment in biomarkers associated with inflammation (CRP, IL-1, IL-6, IL-10, and TNF-α), neurotrophic activity (BDNF), and neuronal injury (NfL, GFAP, BD-tau, and UCH-L1). An exploratory objective is to assess whether biomarker changes differ between participants with and without comorbid post-traumatic stress disorder (PTSD).
Before treatment, participants will undergo medical and behavioral health evaluations to determine their suitability for HBOT. Eligible participants will complete a baseline blood draw for biomarker analysis and standard laboratory testing. Demographic, military service, and relevant clinical information will also be collected.
All participants will receive 40 HBOT sessions in a multiplace chamber at 2.0 atmospheres absolute (ATA). During each session, participants will breathe 100% oxygen for two 30-minute periods separated by a 5-minute air break. Sessions will be scheduled twice daily, Monday through Friday, with at least four hours between sessions. Blood collection and standard laboratory testing will be repeated after the 40-session protocol.
The study will use a pretest-posttest design without randomization or a control group. Within-participant biomarker changes will be evaluated using paired statistical tests, with adjustments for multiple comparisons in the primary biomarker analyses. Comparisons by comorbid PTSD status and associations between biomarker changes and clinical outcomes will be exploratory. Because all participants receive HBOT, observed changes cannot be attributed to HBOT alone.
140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.
This study's planned enrollment of 34 is below the median of 52 across 113 interventional studies indexed under Post-Concussion Syndrome.
Browse Post-Concussion Syndrome studies →Summit Hyperbarics and Wellness is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Compared within Post-Concussion Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Brain Injuries, Traumatic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
4. The participant is willing and able to read, understand, and sign an . Additionally, the participant has clear consciousness and the ability to express self-feelings independently.
6. Completed psychological measurements (pre-study screening requirement) 7. Presence of cognitive and/or PCS symptoms resulting in impairment in occupational, social, and other important areas of functioning, as determined by clinical evaluation.
8. Sexually active female participants of and sexually active male participants with female partners of childbearing potential must agree to use an acceptable method of for the duration of the study and for 30 days following the final HBOT session.
9. Stability on any prescribed psychoactive medications and/or other chronic medical medications. Stability is defined as no significant changes in type of dosage within the previous 4-5 weeks, to minimize confounding effects on study outcomes and ensure participant safety.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive 40 hyperbaric oxygen therapy (HBOT) sessions in a multiplace chamber at 2.0 atmospheres absolute (ATA). Each session will include two 30-minute periods of breathing 100% oxygen, separated by a 5-minute air break. Sessions will occur twice daily, Monday through Friday, with at least four hours between sessions.
Drug: Hyperbaric Oxygen Therapy (HBOT)
Hyperbaric Oxygen Therapy (HBOT): Participants will complete 40 sessions at 2.0 atmospheres absolute (ATA). Each session includes two 30-minute periods of breathing 100% oxygen, separated by a 5-minute air break. Sessions are generally scheduled twice daily with at least four hours between them.
Change in blood C-reactive protein (CRP) concentration
Difference in CRP concentration between baseline and completion of 40 HBOT sessions.
Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in blood interleukin-1 (IL-1) concentration
Difference in IL-1 concentration between baseline and completion of 40 HBOT sessions.
Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in blood interleukin-6 (IL-6) concentration
Difference in IL-6 concentration between baseline and completion of 40 HBOT sessions.
Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in blood interleukin-10 (IL-10) concentration
Difference in IL-10 concentration between baseline and completion of 40 HBOT sessions.
Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in blood tumor necrosis factor-alpha (TNF-α) concentration
Difference in TNF-α concentration between baseline and completion of 40 HBOT sessions.
Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in blood brain-derived neurotrophic factor (BDNF) concentration
Difference in BDNF concentration between baseline and completion of 40 HBOT sessions.
Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in blood neurofilament light chain (NfL) concentration
Difference in NfL concentration between baseline and completion of 40 HBOT sessions.
Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in blood glial fibrillary acidic protein (GFAP) concentration
Difference in GFAP concentration between baseline and completion of 40 HBOT sessions.
Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks)
Change in blood brain-derived tau (BD-tau) concentration
Difference in BD-tau concentration between baseline and completion of 40 HBOT sessions.
Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Change in blood ubiquitin C-terminal hydrolase L1 (UCH-L1) concentration
Difference in UCH-L1 concentration between baseline and completion of 40 HBOT sessions.
Time frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Plan to share: No — There is no current plan to share IPD with researchers outside the study team. Given the small study population and the combination of sensitive clinical and military service information collected, participant-level data sharing could increase the risk of re-identification. Study findings will be reported in aggregate.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Summit Hyperbarics and Wellness